Literature DB >> 21520422

Design strategies for bivalent ligands targeting GPCRs.

Jeremy Shonberg1, Peter J Scammells, Ben Capuano.   

Abstract

Specifically designed bivalent ligands targeting G protein-coupled receptor (GPCR) dimeric structures have become increasingly popular in recent literature. The advantages of the bivalent approach are numerous, including enhanced potency and receptor subtype specificity. However, the use of bivalent ligands as potential pharmacotherapeutics is limited by problematic molecular properties, such as high molecular weight and lipophilicity. This minireview focuses on the design of bivalent ligands recently described in the literature; discussing the choice of lead pharmacophore, the position and nature of the attachment point for linking the two pharmacophore units, and the length and composition of the spacer group. Furthermore, this minireview distils the molecular descriptors of the bivalent ligands that exhibit in vivo activity, as well as highlights their ability to access the central nervous system.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21520422     DOI: 10.1002/cmdc.201100101

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  25 in total

1.  Pharmacological characterization of tachykinin tetrabranched derivatives.

Authors:  Chiara Ruzza; Anna Rizzi; Davide Malfacini; Maria Camilla Cerlesi; Federica Ferrari; Erika Marzola; Caterina Ambrosio; Cristina Gro; Salvadori Severo; Tommaso Costa; Girolamo Calo; Remo Guerrini
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 2.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

Authors:  Ruben S Vardanyan; Victor J Hruby
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

3.  Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers.

Authors:  David A Perrey; Brian P Gilmour; Brian F Thomas; Yanan Zhang
Journal:  ACS Med Chem Lett       Date:  2014-03-25       Impact factor: 4.345

Review 4.  Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Authors:  Christopher Kent Arnatt; Yan Zhang
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

5.  Synthesis and Investigation of Mixed μ-Opioid and δ-Opioid Agonists as Possible Bivalent Ligands for Treatment of Pain.

Authors:  Ruben S Vardanyan; James P Cain; Saghar Mowlazadeh Haghighi; Vlad K Kumirov; Mary I McIntosh; Alexander J Sandweiss; Frank Porreca; Victor J Hruby
Journal:  J Heterocycl Chem       Date:  2016-06-01       Impact factor: 2.193

6.  Synthesis and initial pharmacology of dual-targeting ligands for putative complexes of integrin αVβ3 and PAR2.

Authors:  Mark W Majewski; Disha M Gandhi; Trudy Holyst; Zhengli Wang; Irene Hernandez; Ricardo Rosas; Jieqing Zhu; Hartmut Weiler; Chris Dockendorff
Journal:  RSC Med Chem       Date:  2020-07-09

7.  Chemical biology-based approaches to study adenosine A2A - dopamine D2 receptor heteromers.

Authors:  Karen J Gregory; Manuela Jörg
Journal:  Purinergic Signal       Date:  2022-03-29       Impact factor: 3.765

8.  Novel Bivalent 5-HT2A Receptor Antagonists Exhibit High Affinity and Potency in Vitro and Efficacy in Vivo.

Authors:  Claudia A Soto; Matthew J Shashack; Robert G Fox; Marcy J Bubar; Kenner C Rice; Cheryl S Watson; Kathryn A Cunningham; Scott R Gilbertson; Noelle C Anastasio
Journal:  ACS Chem Neurosci       Date:  2017-11-21       Impact factor: 4.418

9.  Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1.

Authors:  Yuan Fu; Kali A Miller; Lien Nguyen; Amin Haghighat Jahromi; Long M Luu; Anne M Baranger; Steven C Zimmerman
Journal:  J Med Chem       Date:  2013-11-21       Impact factor: 7.446

Review 10.  Design of bivalent ligands targeting putative GPCR dimers.

Authors:  Boshi Huang; Celsey M St Onge; Hongguang Ma; Yan Zhang
Journal:  Drug Discov Today       Date:  2020-10-16       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.